Avience Biomedicals' Rs 30.24 crore IPO, consisting entirely of a fresh issue of 14.54 lakh shares, saw overwhelming investor interest, being subscribed 385.32 times during its three-day bidding period. The strong demand was driven by robust participation across all investor categories.
The non-institutional investor (NII) segment led the demand with a subscription of 597.23 times, while the retail portion was subscribed 401.36 times. The qualified institutional buyer (QIB) category attracted bids for 196.77 times the shares reserved. The IPO price was set at Rs 208 per share, with retail investors required to apply for a minimum of 1,200 shares, equating to an investment of Rs 2.50 lakh.
Incorporated in 2024, Avience Biomedicals specializes in manufacturing, supplying, and exporting molecular diagnostic solutions for the biotechnology, genomics, and in-vitro diagnostics (IVD) industry. The company's product portfolio includes rapid test kits, molecular diagnostic products, biochemistry and hematology analyzers, reagents, and medical devices. It serves pathology laboratories, hospitals, research centers, and government institutions both in India and overseas, while also trading in medical equipment.
The proceeds from the IPO will be utilized to partially fund the establishment of a new manufacturing facility at the Medical Device Park under the Yamuna Expressway Industrial Development Authority in Uttar Pradesh, meet working capital requirements, and for general corporate purposes.
Financially, Avience Biomedicals reported a total income of Rs 45.97 crore and a net profit of Rs 7.23 crore for FY25. For the nine months ended January 2026, the company posted revenue of Rs 41.94 crore and a profit after tax of Rs 5.74 crore.
Background
Avience Biomedicals' IPO success reflects the growing investor interest in the healthcare and diagnostics sector, driven by the company's strong financial performance and strategic expansion plans. The IPO's oversubscription highlights the market's confidence in the company's growth potential.
As Avience Biomedicals prepares for its market debut, investors will be keenly watching the stock's performance post-listing, given the strong subscription rates and the grey market premium indicating a potential 62% premium over the issue price.
